An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...
Clinical trial NCT00924092 · COMPLETED
Trial details
- NCT number
- NCT00924092
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2009-03-13
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.